Asia · Markets & Finance · Yicai Global

Chinese Cancer Drug Developer InnoCare, Eli Lilly Ink Deal Worth up to USD3.35 Billion

Published by Yicai Global · China 7 d ago

(Yicai) Sept. 24 -- China's InnoCare Pharma has signed a research collaboration and licensing agreement with American pharma giant Eli Lilly and Co. to discover innovative drugs,…

Read the full article on Yicai Global Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.yicaiglobal.com)

Also worth reading

CNBC-TV18

SEBI mandates brokers to display investor awareness messages on trading apps and websites

Mint

Azad Engineering share price: Up 86% in 6 months! Is more steam left in this defence stock? Experts' view, target price

The Straits Times Business

Protein drinks and matcha chai: Starbucks patrons in Asia can expect more choice, outlets by 2029

The Business Times

Nuclear fusion conference spotlights Singapore as hub for spin-offs, supply chain

The Economic Times

Trump $500 Obamacare refund from this month

Business Standard